[Antibiotic prophylaxis with prulifloxacin in women undergoing induced abortion: a randomized controlled trial].
OBJECTIVE
To verify the efficacy of prulifloxacin in prevention of infective morbidity in women undergoing first trimester induced abortion. The aim of the study was to observe the incidence of infection during four weeks following abortion by monitoring the symptoms which require general practitioner prescription or hospitalization.


METHODS
Randomized controlled trial carried on by the Research Group for Sexology, Familiar Planning Service of the Department of Microbiological and Gynecological Science, University of Catania from September 2005 to March 2007. The study included 466 women, ranging in age from 14 to 44 years (mean age 26.7), who were randomized in three groups: group A (153 subjects) treated with 600 mg daily of prulifloxacin for 5 days after abortion; group B (155 subjects) treated with 600 mg daily of prulifloxacin for 3 days after abortion; group C (158 subjects) treated with 600 mg daily of prulifloxacin one day before and 2 days after abortion.


RESULTS
Two hundred sixteen were nulliparous (47%), 96 were pluriparous (38.5%). Thirty-two nulliparous (15%) were under eighteen. Among pluriparous, 96 (38.5%) have had previous surgery delivery and 154 (61.5%) spontaneous delivery; moreover, 56 women have had previous surgical interruption during the first-trimester of pregnancy. Surgical abortion was practiced in a range of gestational age between 6th and 11th week of amenorrhea (average week 8.2). The percentage of pelvic inflammatory disease symptoms (pain, fever, leucoxantorrhea ) were about 10.5 in group A, 7.1 in group B and 2.5 in group C. Group C protocol was statistically more effective than group A protocol (P<0.05), but not than group B, even if prevalence of adverse events were less.


CONCLUSIONS
Antibiotic prophylaxis before surgical abortion and shortening supplies after abortion is more effective than post abortion treatment alone.
Caruso
S
S
Dipartimento di Scienze Microbiologiche e Ginecologiche, Università di Catania, Catania, Italy. scaruso@unict.it
Di Mari
L
L
Cacciatore
A
A
Mammana
G
G
Agnello
C
C
Cianci
A
A
D000028:Abortion, Induced / Q000379:methods; D000293:Adolescent; D000328:Adult; D019072:Antibiotic Prophylaxis; D003475:Curettage; D004148:Dioxolanes / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D015994:Incidence; D010298:Parity; D034161:Pelvic Infection / Q000453:epidemiology / Q000517:prevention & control*; D000292:Pelvic Inflammatory Disease / Q000453:epidemiology / Q000517:prevention & control; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D004148:Dioxolanes; D024841:Fluoroquinolones; D010879:Piperazines; D015363:Quinolones; C074191:prulifloxacin